AstraZeneca has agreed to buy Boston-based Modella AI to integrate AI capabilities directly into its oncology R&D organization.
- Modella’s AI foundation models and AI agents will be used to support clinical development and biomarker discovery in cancer research.
- The acquisition expands a prior multi-year collaboration into full integration, signaling a shift from external partnerships toward embedded AI infrastructure.
- This represents one of the first major AI company acquisitions by a large pharmaceutical group, underscoring how AI is becoming core to drug discovery and optimization processes.
🔗 Source: Reuters – AstraZeneca to acquire Modella AI to speed oncology drug research